GE Healthcare Life Sciences and Promosome sign licensing agreement

For mammalian cell line development technologies

GE Healthcare Life Sciences and US-based synthetic biology company Promosome have signed a new licensing agreement under which GE Healthcare has gained exclusive rights to a suite of mammalian cell line development technologies, developed by Promosome, for increasing protein expression in mammalian cell culture.

Under the terms of agreement, Promosome will receive milestone payments for technology transfer and subsequent royalties upon commercialisation.

Morgan Norris, General Manager for Upstream Products, BioProcess, GE Healthcare Life Sciences, said: 'The biopharmaceutical industry is constantly looking for ways to improve efficiency and increase flexibility. Promosome’s technologies provide a powerful way to drive up protein yields and, more excitingly, boost the output of cell lines for hard-to-express proteins to a level where large-scale manufacturing becomes viable and previously disregarded therapies can be progressed.'

John Manzello, President and CEO of Promosome, added: 'This agreement represents a significant commercial milestone for Promosome. We are excited to be working closely with the team at GE Healthcare to transfer our technology to their in-house experts.'

GE Healthcare recently acquired Thermo Fisher’s HyClone cell culture media and sera allowing the company to expand its offering of start-to-finish technologies for the discovery and manufacturing of new medicines and vaccines. In 2012 the company launched KUBio, an off-the-shelf modular factory for the manufacture of monoclonal antibodies.

Companies